Fig. 2.

A: effect of ANG II on systolic blood pressure in phospholipase C-ε1 (Plce1) deficiency. Systolic blood pressure rose equally in all three genotypes after 1 wk of treatment with ANG II. Blood pressure was significantly lower in Plce1^−/− mice at week 2 compared with Plce1^+/+ mice. Blood pressure in Plce1^−/− mice was equivalent to the other two genotypes at week 4. Group sizes for Plce1^+/+, Plce1^+/−, and Plce1^−/− mice were as follows n = 19, 15, and 15 at baseline, n = 18, 11, and 14 at week 1, n = 19, 15, and 15 at week 2, and n = 10, 8, and 8 at week 4, respectively. †P < 0.05 vs. baseline for all three genotypes; ‡P < 0.05 vs. Plce1^+/+ mice at week 2. B: effect of ANG II on albuminuria in Plce1 deficiency. The urine albumin-to-creatinine ratio was significantly higher in Plce1^−/− mice compared with the other two genotypes at weeks 1, 2, and 4 of ANG II infusion. Albuminuria levels were lower at week 2 compared with week 1 in Plce1^−/− mice but were still greater than levels experienced by the other two genotypes. Group sizes for Plce1^+/+, Plce1^+/−, and Plce1^−/− mice were as follows: n = 19, 15, and 15 at baseline, week 1, and week 2, respectively, and n = 10, 8, and 8 at week 4, respectively. *P < 0.05 vs. Plce1^+/+ and Plce1^+/− mice; #P < 0.05 vs. Plce1^−/− mice at week 1.